We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$980M
AUM Growth
+$260M
Cap. Flow
+$316M
Cap. Flow %
32.2%
Top 10 Hldgs %
50.1%
Holding
93
New
25
Increased
16
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$25.5M
2
GLUE icon
Monte Rosa Therapeutics
GLUE
+$18.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.9M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$16.5M
5
IMNM icon
Immunome
IMNM
+$16.1M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$14.2M
2
CGON icon
CG Oncology
CGON
+$11M
3
VRDN icon
Viridian Therapeutics
VRDN
+$10.8M
4
PFE icon
Pfizer
PFE
+$10.4M
5
AVTX icon
Avalo Therapeutics
AVTX
+$9.52M

Sector Composition

Rank Sector Weight
1 Healthcare 85.36%
2 Financials 1.25%

No holdings matched the selected filter criteria.

1 2 3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Silverarc Capital Management held 93 positions worth $980M, up 36% from $720M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management deployed $316M of net new capital in Q1 2026, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Zenas BioPharma: 1,135,935 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Abivax, an estimated $14.2M trimmed.

  • Silverarc Capital Management's largest Q1 2026 buy was Zenas BioPharma: 1,135,935 shares worth $22.2M.
  • Silverarc Capital Management added most to Monte Rosa Therapeutics in Q1 2026, an estimated $18.6M increase.
  • Silverarc Capital Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $14.2M.
  • Silverarc Capital Management fully exited Viridian Therapeutics in Q1 2026, selling an estimated $10.8M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $980M portfolio in Q1 2026.
  • Silverarc Capital Management opened 25 new positions and closed 20 in Q1 2026.
  • Silverarc Capital Management's portfolio value rose 36% quarter-over-quarter to $980M.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.